Intentar ORO - Gratis

Can India Eliminate TB by 2025?

BioSpectrum Asia

|

BioSpectrum Asia March 2023

Tuberculosis (TB) is a severe public health issue in India, accounting for a quarter of the global TB burden.

Can India Eliminate TB by 2025?

While the World Health Organisation (WHO) has set a goal to end the TB epidemic by 2030, India committed to ending the disease by 2025, a mission backed by Prime Minister Narendra Modi. But the crucial question here is whether it is an achievable target?

According to the WHO, only 60 per cent of TB cases in India are notified to the national TB programme. Incidentally, most patients do not seek medical attention at all or are not diagnosed until the disease is in its advanced stages. At this juncture, technology comes in to assist in early and better TB detection. Early detection is a key strategy called out in the Global Plan to End TB.

Challenges on the road

Despite technological advancements, numerous challenges remain in the fight against TB in India. One of the biggest is the lack of access to healthcare in rural and remote locations. Many people in these areas do not have access to the same resources and technology as those living in urban areas. They may not have the necessary awareness to seek medical attention in time; even if they do, the plight of Primary Health Centres (PHCs) in rural locations abates the situation. The PHCs do not have access to diagnostic tools and suffer from a severe shortage of trained personnel to read reports and guide patients onto the correct treatment pathway. All of these factors, coupled with the rising cost of care, make diagnosing and treating TB significantly tougher.

Another challenge is the high number of drugresistant TB cases in India. This type of TB is much harder to treat and requires more expensive, specialised drugs and a longer duration of treatment. Lack of research and an inability to implement measures to cap the treatment and drug costs are aiding the spread of the epidemic. Though India has a detailed National Strategic Plan

MÁS HISTORIAS DE BioSpectrum Asia

BioSpectrum Asia

Repligen introduces next-generation chromatography resins

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, has announced the launch of three new high-performance chromatography resins:

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Hanahealth by DSS Imagetech launches GERI Time-Lapse Incubator in India

Hanahealth by DSS Imagetech, the authorised partner of Sydney-based Genea Biomedx, has launched the advanced GERI Time-Lapse Incubator pan India. GERI, the nextgeneration Time Lapse embryo culture system from Genea Biomedx, is ideal for IVF clinics, labs adopting digital transformation, centres working toward accreditation, and research-focused fertility groups as it enables them to modernise their processes and improve IVF outcomes.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

Biotechnology to Drive Next Industrial Revolution: Dr Jitendra Singh

\"Biotechnology will play a defining role in shaping the next industrial revolution and will be a key driver of global and Indian economic growth\", said Dr Jitendra Singh, the Union Minister of State (Independent Charge) for Science and Technology.

time to read

1 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cartherics names Dr lan Nisbet as CEO

Australia-based Cartherics, a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women's diseases, with lead programmes in ovarian cancer and endometriosis, has announced the appointment of Dr Ian Nisbet as Chief Executive Officer, as part of a planned leadership transition.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Neurophet ropes in Josh Cohen as Head of Americas Business

South Korea-based Neurophet, an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

India's Final Mile to TB Elimination

As the target year 2025 draws to a close, the Government of India has intensified and consolidated nationwide efforts to eliminate tuberculosis (TB) through the TB-Mukt Bharat Abhiyaan, implemented under the National Tuberculosis Elimination Programme (NTEP). India's decision to advance the TB elimination timeline ahead of global targets has driven sustained reforms across detection, treatment, prevention, nutrition support, and community engagement.

time to read

2 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Korea builds AI-engineered nasal spray antiviral platform

A research team at Korea Advanced Institute of Science and Technology has successfully developed a nasal (intranasal) antiviral platform using artificial intelligence (AI) technology to overcome the existing limitations of interferonlambda treatments, namely, being weak against heat and disappearing quickly from the nasal mucosa.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

"Industry needs to evolve and invest in ADC payloads with more differentiated mechanisms of action

Antibody drug conjugates (ADCs) are becoming highly valuable in the market, with currently 15 approved ADCs targeting 16 different indications for haematological and solid tumour malignancies. With key components of ADCs, such as mAbs, linkers, payloads, and conjugation technologies, undergoing rapid advancements, a solid foundation has been laid for future research and development in this field, particularly in North America which is the largest market shareholder for ADCs. US recently wrapped up the world's largest & definitive Antibody-Drug Conjugate event, World ADC, held in November 2025, highlighting the development of novel ADCs through key market players, and a surge in patent application filing for ADCs. Dr Allan Jordan, Vice President of Oncology Drug Discovery at Sygnature Discovery, UK spoke in detail with BioSpectrum Asia about the future outlook of ADCs.

time to read

4 mins

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

Cytiva and Fida Biosystems collaborate to improve molecular insight for faster drug discovery

Cytiva, a Danaher company and leader in the life sciences industry, and Fida Biosystems, a Danish company specialising in molecular analysis, have joined forces to expand analytical capabilities for protein research.

time to read

1 min

BioSpectrum Asia Jan 2026

BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Excellence Awards Highlight Strength and Future of India's Biotechnology Sector

Former Secretary, Department of Biotechnology (DBT), Government of India, Dr Renu Swarup, underscored the importance of recognising excellence across the biotechnology ecosystem while chairing the jury at the BioSpectrum Excellence Awards.

time to read

1 min

BioSpectrum Asia Jan 2026

Translate

Share

-
+

Change font size